CRYOPORT INC (CYRX) Fundamental Analysis & Valuation

NASDAQ:CYRX • US2290503075

7.88 USD
-0.21 (-2.6%)
At close: Mar 10, 2026
7.95 USD
+0.07 (+0.89%)
After Hours: 3/10/2026, 8:16:32 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CYRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall CYRX gets a fundamental rating of 3 out of 10. We evaluated CYRX against 57 industry peers in the Life Sciences Tools & Services industry. While CYRX seems to be doing ok healthwise, there are quite some concerns on its profitability. CYRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. CYRX Profitability Analysis

1.1 Basic Checks

  • CYRX had positive earnings in the past year.
  • In the past year CYRX has reported a negative cash flow from operations.
  • In the past 5 years CYRX reported 4 times negative net income.
  • In the past 5 years CYRX reported 4 times negative operating cash flow.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • With an excellent Return On Assets value of 8.71%, CYRX belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 13.25%, CYRX belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
Industry RankSector Rank
ROA 8.71%
ROE 13.25%
ROIC N/A
ROA(3y)-6.5%
ROA(5y)-9.87%
ROE(3y)-12.85%
ROE(5y)-18.18%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • CYRX's Profit Margin of 37.81% is amongst the best of the industry. CYRX outperforms 100.00% of its industry peers.
  • Looking at the Gross Margin, with a value of 47.14%, CYRX is in line with its industry, outperforming 50.88% of the companies in the same industry.
  • CYRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 37.81%
GM 47.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y0.44%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CYRX Health Analysis

2.1 Basic Checks

  • CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CYRX has about the same amout of shares outstanding than it did 1 year ago.
  • CYRX has more shares outstanding than it did 5 years ago.
  • CYRX has a better debt/assets ratio than last year.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • CYRX has an Altman-Z score of 0.14. This is a bad value and indicates that CYRX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.14, CYRX is doing worse than 68.42% of the companies in the same industry.
  • CYRX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • CYRX has a Debt to Equity ratio of 0.00. This is in the better half of the industry: CYRX outperforms 70.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.14
ROIC/WACCN/A
WACC9.29%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.17 indicates that CYRX has no problem at all paying its short term obligations.
  • The Current ratio of CYRX (2.17) is comparable to the rest of the industry.
  • A Quick Ratio of 2.07 indicates that CYRX has no problem at all paying its short term obligations.
  • CYRX has a Quick ratio (2.07) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 2.07
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CYRX Growth Analysis

3.1 Past

  • CYRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 218.97%, which is quite impressive.
  • Looking at the last year, CYRX shows a very negative growth in Revenue. The Revenue has decreased by -22.86% in the last year.
  • CYRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.49% yearly.
EPS 1Y (TTM)218.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-22.86%
Revenue growth 3Y-9.45%
Revenue growth 5Y17.49%
Sales Q2Q%-23.65%

3.2 Future

  • The Earnings Per Share is expected to decrease by -17.15% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 8.52% on average over the next years. This is quite good.
EPS Next Y-151%
EPS Next 2Y-56.85%
EPS Next 3Y-29.61%
EPS Next 5Y-17.15%
Revenue Next Year9.12%
Revenue Next 2Y9.34%
Revenue Next 3Y8.03%
Revenue Next 5Y8.52%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. CYRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.71, which indicates a rather cheap valuation of CYRX.
  • Based on the Price/Earnings ratio, CYRX is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • CYRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.25.
  • The Forward Price/Earnings Ratio is negative for CYRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.71
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as CYRX's earnings are expected to decrease with -29.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.85%
EPS Next 3Y-29.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYRX Dividend Analysis

5.1 Amount

  • CYRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYRX Fundamentals: All Metrics, Ratios and Statistics

CRYOPORT INC

NASDAQ:CYRX (3/10/2026, 8:16:32 PM)

After market: 7.95 +0.07 (+0.89%)

7.88

-0.21 (-2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-03
Earnings (Next)05-05
Inst Owners96.76%
Inst Owner Change0.2%
Ins Owners3.99%
Ins Owner Change0.72%
Market Cap394.55M
Revenue(TTM)176.18M
Net Income(TTM)66.61M
Analysts85.33
Price Target13.49 (71.19%)
Short Float %5.36%
Short Ratio7.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.13%
Min EPS beat(2)-0.16%
Max EPS beat(2)16.41%
EPS beat(4)3
Avg EPS beat(4)246.45%
Min EPS beat(4)-0.16%
Max EPS beat(4)957.28%
EPS beat(8)5
Avg EPS beat(8)130.63%
EPS beat(12)7
Avg EPS beat(12)54.08%
EPS beat(16)7
Avg EPS beat(16)32.54%
Revenue beat(2)2
Avg Revenue beat(2)4.34%
Min Revenue beat(2)3.81%
Max Revenue beat(2)4.86%
Revenue beat(4)3
Avg Revenue beat(4)2.54%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)6.79%
Revenue beat(8)3
Avg Revenue beat(8)-0.68%
Revenue beat(12)3
Avg Revenue beat(12)-1.37%
Revenue beat(16)4
Avg Revenue beat(16)-2.27%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.65%
EPS NY rev (1m)-4.02%
EPS NY rev (3m)-1.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 5.71
Fwd PE N/A
P/S 2.24
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)1.38
EY17.51%
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS3.52
BVpS10.04
TBVpS6.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number17.66
Profitability
Industry RankSector Rank
ROA 8.71%
ROE 13.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 37.81%
GM 47.14%
FCFM N/A
ROA(3y)-6.5%
ROA(5y)-9.87%
ROE(3y)-12.85%
ROE(5y)-18.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.49%
GM growth 5Y0.44%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.38%
Cap/Sales 11.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.17
Quick Ratio 2.07
Altman-Z 0.14
F-Score5
WACC9.29%
ROIC/WACCN/A
Cap/Depr(3y)100.96%
Cap/Depr(5y)106.53%
Cap/Sales(3y)17.09%
Cap/Sales(5y)14.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)218.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-151%
EPS Next 2Y-56.85%
EPS Next 3Y-29.61%
EPS Next 5Y-17.15%
Revenue 1Y (TTM)-22.86%
Revenue growth 3Y-9.45%
Revenue growth 5Y17.49%
Sales Q2Q%-23.65%
Revenue Next Year9.12%
Revenue Next 2Y9.34%
Revenue Next 3Y8.03%
Revenue Next 5Y8.52%
EBIT growth 1Y45.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year116.92%
EBIT Next 3Y43.06%
EBIT Next 5Y25%
FCF growth 1Y25.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.44%
OCF growth 3YN/A
OCF growth 5YN/A

CRYOPORT INC / CYRX FAQ

What is the ChartMill fundamental rating of CRYOPORT INC (CYRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYRX.


Can you provide the valuation status for CRYOPORT INC?

ChartMill assigns a valuation rating of 2 / 10 to CRYOPORT INC (CYRX). This can be considered as Overvalued.


What is the profitability of CYRX stock?

CRYOPORT INC (CYRX) has a profitability rating of 3 / 10.


What are the PE and PB ratios of CRYOPORT INC (CYRX) stock?

The Price/Earnings (PE) ratio for CRYOPORT INC (CYRX) is 5.71 and the Price/Book (PB) ratio is 0.78.


How financially healthy is CRYOPORT INC?

The financial health rating of CRYOPORT INC (CYRX) is 4 / 10.